Back to News
Market Impact: 0.4
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO says
Source: reuters.com
Corporate Guidance & OutlookHealthcare & BiotechProduct Launches
Novo Nordisk targets launches of more than five blockbuster drugs by 2030 and pipeline sales exceeding DKr150 billion ($23 billion) by 2035. CEO Mike Doustdar presented the long-term growth ambitions at the company’s Capital Markets Day in London, signaling a substantial expansion of its drug portfolio and revenue base.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
NVO0.72
More News
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
- Iran & China at Forefront of Trading Week, Critical Metals Rally & NVO Slides
- Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goals
- Why Novo Nordisk Stock Just Crashed
- Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug